Combination of Rapamycin and Trametinib Significantly Extends Mouse Lifespan by 30%

Researchers at the Max Planck Institute for Biology of Aging have made a groundbreaking discovery indicating that a combination of two cancer drugs, rapamycin and trametinib, can noticeably prolong the lifespan of mice. The study, published in Nature Aging, reveals that while trametinib alone can increase lifespan by 5–10% and rapamycin by 15–20%, their combined use results in an impressive 30% extension. This synergy not only extends life but also improves overall health in aged mice, reducing chronic inflammation and delaying cancer onset.

Both drugs target different components of the Ras/Insulin/TOR metabolic network, which plays a crucial role in aging processes. Rapamycin is well-known as a geroprotector that enhances longevity, and trametinib acts on the Ras/MEK/ERK pathway. Notably, the combination influences gene activity in a unique manner, inducing specific genetic changes not seen with individual treatments.

The team plans to optimize dosage and delivery methods for trametinib to maximize benefits and minimize side effects, considering its existing approval for human use. These developments pave the way for clinical trials aimed at evaluating the potential of this drug combo as a geroprotective therapy.

While researchers caution that the extent of lifespan extension observed in mice may not directly translate to humans, the findings are promising for future strategies to promote healthy aging. The study suggests that such combination therapy could become a potent approach to combat age-related diseases and enhance quality of life in later years.

For more details, see the full study in Nature Aging (2025). Source.